Patent US5330972A successfully refreshed from Google Patents.
US5330972A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
Assignee: Abbott Laboratories
•
Filing: 1993-05-28
•
Granted: 1994-07-19
•
Expires: 2013-05-28
Abstract
Abstract The apoptosis of CD4 cells in a person infected with the human immunodeficiency virus may be impeded by enterally feeding to the infected person a nutritional product which contains soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30%-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.
Inventors
- 👤 Frederick O. Cope
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 00:52
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A23; A23L; A23L33/00; A23L33/40; A61K31/00; A61K31/185; A61K31/19; A61K38/00; A61K38/01; A61K38/011; Y; Y10; Y10S; Y10S426/00; Y10S426/80
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
166 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus comprising enterally feeding to said person a therapeutically effective amount of an enteral nutritional product comprising: (a) a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography wherein 30%-60% of the particles have a molecular weight in the range of 1500-5000 Daltons and the amino acid profile of the soy protein hydrolysate has less than 1% free amino acids; (b) a second source of protein which comprises a source of intact protein in a quantity sufficient to yield a stable emulsification of the soy protein hydrolysate and the intact protein in the nutritional product; and (c) a source of fat characterized by the ratio, by weight, of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids being in the range of about 1.3:1 to 2.5:1.
Claim 2
Independent Claim
166 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus comprising enterally feeding to said person a therapeutically effective amount of an enteral nutritional product comprising: (a) a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography wherein 30%-60% of the particles have a molecular weight in the range of 1500-5000 Daltons and the amino acid profile of the soy protein hydrolysate has less than 1% free amino acids; (b) a second source of protein which comprises a source of intact protein in a quantity sufficient to yield a stable emulsification of the soy protein hydrolysate and the intact protein in the nutritional product; and (c) a source of fat characterized by the ratio, by weight, of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids being in the range of about 1.3:1 to 2.5:1.
Claim 3
Dependent Claim
81 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 1 wherein the soy protein hydrolysate has the following amino acid profile in g/100 g of the soy protein hydrolysate: ______________________________________
Aspartic acid 9.8-10.4
Threonine 2.9-3.2
Serine 3.7-4.4
Glutamic Acid 17.0-18.1
Proline 4.4-4.9
Glycine 3.2-3.3
Alanine 3.0-3.2
Valine 2.9-3.6
Methionine 0.9-1.1
Isoleucine 3.0-3.7
Leucine 5.1-5.3
Tyrosine 2.7-2.9
Phenylalanine 3.3-3.5
Histidine 2.0-2.2
Lysine 5.5-5.8
Arginine 6.3-6.7
Tryptophan 0.3-0.7
Cystine 1.3-1.4
______________________________________
Claim 4
Dependent Claim
86 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 1 wherein the soy protein hydrolysate has the following mineral profile: ______________________________________
Calcium, mg/100 g 170-350
Sodium, mg/100 g 370-650
Potassium, mg/100 g
180-600
Magnesium, mg/100 g
270-550
Phosphorus, mg/100 g
900-1500
Chloride, mg/100 g
1400-2500
Iron, mg/100 g 13-25
Zinc, mg/100 g 3-6
Manganese, mg/100 g
4-8
Copper, mg/100 g 0.5-1.5
Vanadium, ppm trace-15
Selenium, ppb trace-350
Chromium, ppm trace-2.9
Molybdenum, ppm trace-3.7
______________________________________
Claim 5
Dependent Claim
86 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 2 wherein the soy protein hydrolysate has the following mineral profile: ______________________________________
Calcium, mg/100 g 170-350
Sodium, mg/100 g 370-650
Potassium, mg/100 g
180-600
Magnesium, mg/100 g
270-550
Phosphorus, mg/100 g
900.1500
Chloride, mg/100 g
1400-2500
Iron, mg/100 g 13-25
Zinc, mg/100 g 3-6
Manganese, mg/100 g
4-8
Copper, mg/100 g 0.5-1.5
Vanadium, ppm trace-15
Selenium, ppb trace-350
Chromium, ppm trace-2.9
Molybdenum, ppm trace-3.7
______________________________________
Claim 6
Dependent Claim
44 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 1 wherein the soy protein hydrolysate is further characterized in that a 5% slurry, by weight, has a pH of less than 4.5.
Claim 7
Dependent Claim
51 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 1 wherein the soy protein hydrolysate comprises, by weight,: (a) not less than 80% protein; (b) not more than % fat; and ( c ) not more than 5.5% ash.
Claim 8
Dependent Claim
33 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 1 wherein the soy protein hydrolysate was hydrolyzed with an alkaline proteinase.
Claim 9
Dependent Claim
30 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 1 wherein the degree of hydrolysis is about 16.0.
Claim 10
Dependent Claim
30 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 2 wherein the degree of hydrolysis is about 16.0.
Claim 11
Dependent Claim
30 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 3 wherein the degree of hydrolysis is about 16.0.
Claim 12
Dependent Claim
30 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 4 wherein the degree of hydrolysis is about 16.0.
Claim 13
Dependent Claim
30 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 5 wherein the degree of hydrolysis is about 16.0.
Claim 14
Dependent Claim
30 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 6 wherein the degree of hydrolysis is about 16.0.
Claim 15
Dependent Claim
30 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 7 wherein the degree of hydrolysis is about 16.0.
Claim 16
Dependent Claim
34 words
A method of impeding the apoptosis of CD4 cells in a persons infected with human immunodeficiency virus as described in claim 1 wherein the enteral nutritional product further comprises a source of dietary fiber.
Claim 17
Dependent Claim
37 words
A method of impeding the apoptosis of CD4 cells in a person infected with human immunodeficiency virus as described in claim 1 wherein the enteral nutritional product further comprises soy polysaccharide as a source of dietary fiber.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-07-18 | 1998-01-17 | 1998-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-07-18 | 2002-01-17 | 2002-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-07-18 | 2006-01-17 | 2006-07-19 | $7700.00 | Window Closed / Lapsed |